WEBULL
WebtradeDownload

Ascendis Pharma (ASND) Stock May Trade At A Discount As EU Exclusivity Nears

Simply Wall St · 2d ago

Ascendis Pharma has quietly put together a solid run over the past month, which puts a fresh spotlight on whether the current share price lines up with what its earnings can support. With fresh trial data and European regulatory momentum now in the mix, the question is how much of that promise is already reflected in the valuation.

  • The stock has returned 12.4% over the past month, which puts more pressure on the earnings picture to justify the stronger pricing.
  • New updates on TransCon CNP and TransCon PTH may support expectations for future profitability, since they speak directly to potential revenue durability and the timing of cash generation from Ascendis Pharma's pipeline.
  • There is a second opinion on Ascendis Pharma worth weighing. See what analysts think Ascendis Pharma's shares could be worth.

The stock's next move may depend on whether Ascendis Pharma's current earnings are enough to warrant where the market is pricing it today.

If you are weighing whether Ascendis Pharma's earnings support its recent 12.4% move, it can help to compare that question across 39 high quality undervalued stocks.

Is Ascendis Pharma a Bargain on Earnings?

P/E works well for Ascendis Pharma because investors are focused on how current earnings relate to a maturing pipeline. The stock trades on a P/E of about 20.4x, which is below the biotech sector average of roughly 15.4x but also below the peer group level of around 22.6x. That mix indicates the market is assigning a premium to Ascendis relative to the broader biotech sector, yet not giving it the richest label within its closer peer set.

Once weekly TransCon CNP progressing toward potential EU approval and the long term TransCon PTH data both feed into how durable those earnings could be. Despite that attention, the multiple still screens below what a more tailored fair P/E would suggest for a business with these characteristics. The current ratio sits under the level implied by the fair benchmark that factors in Ascendis Pharma's growth profile, profitability potential and risk, which indicates the stock is screening as undervalued on this metric. Explore the numbers behind Ascendis Pharma's P/E valuation.

NasdaqGS:ASND P/E Ratio as at Nov 2026
NasdaqGS:ASND P/E Ratio as at Nov 2026

The Ascendis Pharma Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ascendis Pharma pick up where the P/E puzzle leaves off by spelling out the specific paths for growth, margins and earnings that would need to play out for the stock to be worth noticeably more or less than today’s share price on the Community page. Each one ties its number to a concrete view of how Ascendis Pharma's growth, profitability and risks could evolve, which you can come back to as fresh information emerges.

One of the top community narratives on Ascendis Pharma: 16% undervalued

"Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies..."

Discover why this Narrative puts Ascendis Pharma at 16% undervalued.

One more angle on Ascendis Pharma that could shift how you see the stock

Price multiples and pipeline stories only go so far without a view on where professionals think earnings could land a few years from now, and how that stacks up against today's tag. Explore where analysts expect Ascendis Pharma to be in a few years.